APOE shifts the tipping point: addressing pathological heterogeneity in Alzheimer's disease trials
Brain · 03.06.2026 · 149 (6) · 1801-1803
DOI: 10.1093/brain/awag151 ↗Kurz gefasst
Kommentar in der Zeitschrift Brain, online erschienen am 29.04.2026. Verfasst von Duygu Tosun. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94121, USA. Die Arbeit nennt 9 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
This scientific commentary refers to ‘ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner’ by Steward et al. (https://doi.org/10.1093/brain/awaf463).
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA 94121, USA.
ORCID-Profile: Duygu Tosun
Zitieren
APA
Tosun, D. (2026). APOE shifts the tipping point: addressing pathological heterogeneity in Alzheimer's disease trials. Brain, 149(6), 1801-1803. https://doi.org/10.1093/brain/awag151
Vancouver
Tosun D. APOE shifts the tipping point: addressing pathological heterogeneity in Alzheimer's disease trials. Brain. 2026;149(6):1801-1803. doi:10.1093/brain/awag151
BibTeX
@article{Tosun2026,
author = {Tosun, Duygu},
title = {APOE shifts the tipping point: addressing pathological heterogeneity in Alzheimer's disease trials},
journal = {Brain},
year = {2026},
volume = {149},
number = {6},
pages = {1801--1803},
doi = {10.1093/brain/awag151}
}
EUVIMED